DK2994533T3 - Fremgangsmåder og sammensætninger til behandling af cancer - Google Patents
Fremgangsmåder og sammensætninger til behandling af cancer Download PDFInfo
- Publication number
- DK2994533T3 DK2994533T3 DK14722204.6T DK14722204T DK2994533T3 DK 2994533 T3 DK2994533 T3 DK 2994533T3 DK 14722204 T DK14722204 T DK 14722204T DK 2994533 T3 DK2994533 T3 DK 2994533T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20130382167 EP2801370A1 (en) | 2013-05-07 | 2013-05-07 | Methods and compositions for the treatment of cancer |
| PCT/EP2014/059315 WO2014180889A1 (en) | 2013-05-07 | 2014-05-07 | Methods and compositions for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2994533T3 true DK2994533T3 (da) | 2019-07-01 |
Family
ID=48366303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14722204.6T DK2994533T3 (da) | 2013-05-07 | 2014-05-07 | Fremgangsmåder og sammensætninger til behandling af cancer |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10370434B2 (da) |
| EP (4) | EP2801370A1 (da) |
| JP (2) | JP6722103B2 (da) |
| KR (1) | KR102324116B1 (da) |
| CN (1) | CN105378084B (da) |
| AU (1) | AU2014264642B2 (da) |
| BR (2) | BR112015028115B1 (da) |
| CA (1) | CA2911863A1 (da) |
| CY (1) | CY1121849T1 (da) |
| DK (1) | DK2994533T3 (da) |
| EA (2) | EA202090683A3 (da) |
| ES (1) | ES2733515T3 (da) |
| HK (1) | HK1251494A1 (da) |
| HR (1) | HRP20191330T1 (da) |
| HU (1) | HUE045615T2 (da) |
| IL (2) | IL242483B (da) |
| LT (1) | LT2994533T (da) |
| ME (1) | ME03509B (da) |
| MX (1) | MX370792B (da) |
| PL (1) | PL2994533T3 (da) |
| PT (1) | PT2994533T (da) |
| RS (1) | RS59276B1 (da) |
| SG (2) | SG10201709101VA (da) |
| SI (1) | SI2994533T1 (da) |
| SM (1) | SMT201900423T1 (da) |
| WO (1) | WO2014180889A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2801370A1 (en) | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
| US10654894B2 (en) * | 2016-02-03 | 2020-05-19 | Keenesaw State University Research And Service Foundation, Inc. | Methods for delivering cargo into a cell by using signal molecules as cell penetration agents |
| US20190135868A1 (en) * | 2016-04-29 | 2019-05-09 | The University Of Chicago | Synthetic dna binding domain peptides and uses thereof |
| EP3269734A1 (en) * | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
| CN106591335A (zh) * | 2016-11-08 | 2017-04-26 | 安徽省农业科学院水稻研究所 | 一种密码子植物化改造的LbCpf1基因及其应用 |
| CA3091948A1 (en) * | 2017-09-08 | 2019-03-14 | Idp Discovery Pharma, S.L. | New treatments of multiple myeloma |
| SG11202004861UA (en) * | 2017-11-29 | 2020-06-29 | Agency Science Tech & Res | Chimeric molecule for targeting c-myc in cells |
| JP7474702B2 (ja) | 2018-03-28 | 2024-04-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法 |
| US20210024936A1 (en) * | 2018-04-09 | 2021-01-28 | Board Of Regents, The University Of Texas System | Therapeutic targeting of oncogenes using exosomes |
| CA3126544A1 (en) * | 2019-01-12 | 2020-07-16 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| TWI829893B (zh) * | 2019-03-19 | 2024-01-21 | 瓦爾希伯倫私人腫瘤研究基金會 | 診斷肺癌的方法 |
| EP3941503A1 (en) * | 2019-03-19 | 2022-01-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
| CN114174313A (zh) | 2019-04-09 | 2022-03-11 | 芝加哥大学 | 采用狄尔斯-阿尔德环加成反应的通用型肽和蛋白质的大环化和多聚化 |
| KR102221227B1 (ko) | 2019-05-07 | 2021-03-03 | 김영화 | 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법 |
| US20220307013A1 (en) * | 2019-08-30 | 2022-09-29 | The Regents Of The University Of California | Gene fragment overexpression screening methodologies, and uses thereof |
| CN115925975B (zh) * | 2022-08-03 | 2024-09-17 | 山东大学 | 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用 |
| EP4361633A1 (en) | 2022-10-25 | 2024-05-01 | Peptomyc, S.L. | Method for predicting response to a cancer treatment |
| EP4446742A1 (en) | 2023-04-14 | 2024-10-16 | Peptomyc, S.L. | Method for assessing or monitoring the response to a cancer treatment |
| EP4473974A1 (en) * | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| WO2025064985A1 (en) * | 2023-09-22 | 2025-03-27 | Ohio State Innovation Foundation | Myc INHIBITOR PROTEINS AND USES THEREOF |
| CN118324872A (zh) * | 2024-04-19 | 2024-07-12 | 国家纳米科学中心 | 靶向kras突变蛋白的多肽及其应用 |
| CN118557561A (zh) * | 2024-05-16 | 2024-08-30 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 9-十六烯酸在制备防治结直肠肿瘤的产品及其作为化疗药物的增效剂中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US5322801A (en) | 1990-04-19 | 1994-06-21 | The General Hospital Corporation | Protein partner screening assays and uses thereof |
| EP0633933A1 (en) | 1992-03-23 | 1995-01-18 | Imperial Cancer Research Technology Limited | Leucine zippers |
| EP1342781A1 (en) * | 2002-03-09 | 2003-09-10 | ARTEMIS Pharmaceuticals GmbH | Recombinase fusion protein with enhanced cellular uptake |
| GB0413730D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2011034954A1 (en) * | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | Treatment of cancer |
| DE102009052866A1 (de) | 2009-11-13 | 2011-05-19 | Bizerba Gmbh & Co. Kg | Schneidemaschine |
| EP2544686A4 (en) | 2010-02-05 | 2013-06-26 | Whitehead Biomedical Inst | COMBINATION PROCEDURE FOR THE TREATMENT OF A DISEASE |
| SG186347A1 (en) | 2010-06-14 | 2013-01-30 | Hoffmann La Roche | Cell-penetrating peptides and uses therof |
| US9241920B2 (en) * | 2011-10-27 | 2016-01-26 | New York University | Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression |
| EP2801370A1 (en) | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
-
2013
- 2013-05-07 EP EP20130382167 patent/EP2801370A1/en not_active Withdrawn
-
2014
- 2014-05-07 KR KR1020157034532A patent/KR102324116B1/ko active Active
- 2014-05-07 SM SM20190423T patent/SMT201900423T1/it unknown
- 2014-05-07 CA CA2911863A patent/CA2911863A1/en active Pending
- 2014-05-07 EP EP14722204.6A patent/EP2994533B1/en active Active
- 2014-05-07 HR HRP20191330TT patent/HRP20191330T1/hr unknown
- 2014-05-07 BR BR112015028115-0A patent/BR112015028115B1/pt active IP Right Grant
- 2014-05-07 AU AU2014264642A patent/AU2014264642B2/en active Active
- 2014-05-07 JP JP2016512358A patent/JP6722103B2/ja active Active
- 2014-05-07 SG SG10201709101VA patent/SG10201709101VA/en unknown
- 2014-05-07 SI SI201431286T patent/SI2994533T1/sl unknown
- 2014-05-07 ME MEP-2019-203A patent/ME03509B/me unknown
- 2014-05-07 RS RSP20190840 patent/RS59276B1/sr unknown
- 2014-05-07 MX MX2015015518A patent/MX370792B/es active IP Right Grant
- 2014-05-07 PT PT14722204T patent/PT2994533T/pt unknown
- 2014-05-07 ES ES14722204T patent/ES2733515T3/es active Active
- 2014-05-07 HU HUE14722204A patent/HUE045615T2/hu unknown
- 2014-05-07 CN CN201480032555.2A patent/CN105378084B/zh active Active
- 2014-05-07 WO PCT/EP2014/059315 patent/WO2014180889A1/en not_active Ceased
- 2014-05-07 BR BR122020017819-1A patent/BR122020017819B1/pt active IP Right Grant
- 2014-05-07 PL PL14722204T patent/PL2994533T3/pl unknown
- 2014-05-07 DK DK14722204.6T patent/DK2994533T3/da active
- 2014-05-07 US US14/889,656 patent/US10370434B2/en active Active
- 2014-05-07 EA EA202090683A patent/EA202090683A3/ru unknown
- 2014-05-07 LT LTEP14722204.6T patent/LT2994533T/lt unknown
- 2014-05-07 EP EP19172033.3A patent/EP3545966A1/en active Pending
- 2014-05-07 SG SG11201509131VA patent/SG11201509131VA/en unknown
- 2014-05-07 EA EA201690159A patent/EA035463B1/ru unknown
- 2014-05-07 EP EP18153052.8A patent/EP3338789A1/en active Pending
-
2015
- 2015-11-05 IL IL242483A patent/IL242483B/en active IP Right Grant
-
2018
- 2018-08-31 HK HK18111179.0A patent/HK1251494A1/en unknown
-
2019
- 2019-02-22 JP JP2019030931A patent/JP6790148B2/ja active Active
- 2019-06-06 US US16/433,438 patent/US11339205B2/en active Active
- 2019-07-26 CY CY20191100800T patent/CY1121849T1/el unknown
-
2020
- 2020-03-05 IL IL273090A patent/IL273090B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282202A (en) | Compositions and methods for personalized neoplasia vaccines | |
| DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK2941258T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK3245225T3 (da) | Sammensætninger og fremgangsmåder til behandling og detektering af cancere | |
| DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3035955T3 (da) | Sammensætning og vaccine til behandling af lungekræft | |
| BR112017011771A2 (pt) | métodos e composições para o tratamento de câncer | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3046583T3 (da) | Viruslignende partikelkonjugater til behandling af tumorer | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
| DK3071215T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| IL241461B (en) | Methods for treating osteogenesis imperfecta | |
| DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
| DK3033081T3 (da) | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria |